In the absence of a submission from the holder of the marketing authorisation, cangrelor (Kengrexal®) cannot be endorsed for use within NHS Wales co-administered with acetylsalicyclic acid (ASA) for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.